IPIX (Innovation Pharmaceuticals) Shares Outstanding (EOP): 518.35 Mil (As of Sep. 2023)


What is Innovation Pharmaceuticals Shares Outstanding (EOP)?

Innovation Pharmaceuticals IPIX Shares Outstanding (EOP) is 518.35 Mil as of Sep. 2023.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Innovation Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2023 was 518.35 Mil.

Innovation Pharmaceuticals's quarterly shares outstanding stayed the same from Jun. 2023 (518.35 Mil) to Sep. 2023 (518.35 Mil).

Innovation Pharmaceuticals's annual shares outstanding increased from Jun. 2022 (503.87 Mil) to Jun. 2023 (518.35 Mil). It means Innovation Pharmaceuticals issued new shares from Jun. 2022 to Jun. 2023 .


Innovation Pharmaceuticals  (OTCPK:IPIX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Innovation Pharmaceuticals Shares Outstanding (EOP) Related Terms


Innovation Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Shares Outstanding (EOP) Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 203.31 330.99 433.80 503.87 518.35

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 503.96 492.66 515.99 518.35 518.35

IPIX vs AXIM, RNAZ, APTX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Shares Outstanding (EOP) falls into.



Innovation Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 518.35 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Shares Outstanding (EOP) of 518.35 Mil as of Sep. 2023. The total shares a company has outstanding, at period-end. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Shares Outstanding (EOP) too high?
Innovation Pharmaceuticals' current Shares Outstanding (EOP) is 518.35 Mil.
How does Innovation Pharmaceuticals' Shares Outstanding (EOP) compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Shares Outstanding (EOP) of 518.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Shares Outstanding (EOP) is 518.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Shares Outstanding (EOP) of 518.35 Mil. The current Shares Outstanding (EOP) is 518.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Shares Outstanding (EOP) is 518.35 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.